Study refutes suspicion that dengue increases risk of microcephaly associated with zika
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Researchers compared data for pregnant women in two cities who were infected by zika virus in 2015-16. Factors that influenced the risk of fetal malformation were the high zika attack rate in the area and being infected in the first trimester of pregnancy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 20, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

The Big Number: 12 out of 200 types of mosquitoes spread diseases in the U.S.
West Nile, Zika, dengue and malaria are among the illnesses that some of these insects can carry. But there are ways to stem the spread of mosquito-borne diseases. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 10, 2021 Category: Consumer Health News Authors: Linda Searing Source Type: news

6-member team dispatched to monitor Zika virus in Kerala; no case of Lambda variant detected yet, says Centre
(Source: The Economic Times)
Source: The Economic Times - July 9, 2021 Category: Consumer Health News Source Type: news

Zika detected in Kerala: Know all about symptoms, history, and transmission
With a 24-year-old pregnant woman being found infected with the mosquito-borne Zika virus in Kerala, its state health department has issued an alert. There are 13 other suspected cases of the virus from Thiruvananthapuram as well. (Source: The Economic Times)
Source: The Economic Times - July 9, 2021 Category: Consumer Health News Source Type: news

Zika virus case reported in India: Symptoms, treatment & other key things to know
Zika virus is spread by Aedes aegypti — the same mosquito that is also responsible for causing dengue and chikungunya. The virus is considered a huge cause for worry for pregnant women because it causes microcephaly, a birth defect. (Source: The Economic Times)
Source: The Economic Times - July 9, 2021 Category: Consumer Health News Source Type: news

Mapping dengue hot spots pinpoints risk for Zika and chikungunya
(Emory Health Sciences) Data from nine cities in Mexico confirms that identifying dengue fever " hot spots " can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2021 Category: Infectious Diseases Source Type: news

Ultrasound finds brain differences in infants exposed to Zika virus
Cranial ultrasound found lenticulostriate vasculopathy to be more common i...Read more on AuntMinnie.comRelated Reading: Ultrasound of infants exposed to Zika predicts long-term risk Brain abnormalities on CT, MRI indicate severe Zika Can prenatal ultrasound predict Zika infection outcomes? Digisonics launches website for Zika-related brain disease Zika's effects hard to detect on ultrasound, MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2021 Category: Radiology Source Type: news

Tanzania: Media Should Be Additionally Empowered in Covid-19 Fight
[Daily News] SURELY, the world has seen several outbreaks of natural disasters of earthquakes, tsunami and predicted how to be alerted if another one is on the edge of erupting, but failed on diseases like Ebola virus, Yellow Fever, Zika, Influenza, Cholera, you name it including the Spanish flu that killed more than 50 million people more than the death toll from the First World War. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 24, 2021 Category: African Health Source Type: news

The 10 Most Important Health Breakthroughs You Missed During the Pandemic
While most eyes were on COVID-19, researchers have also made groundbreaking advancements in other fields. Here’s a look. The other big vaccine news Public-health officials have long sought a vaccine against malaria, which infects up to 600 million people a year and kills 400,000, mostly children. This year, there was dramatic prog­ress toward that goal. In a study of 450 children in Burkina Faso, published in the Lancet in April, researchers reported that a new malaria vaccine, called R21, is 77% effective—just clearing the World Health Organization’s 75% efficacy standard. However, the sample gro...
Source: TIME: Health - June 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 feature Innovation Magazine Source Type: news

Preventing the Next Health Crisis Depends on Health Workers. We Need 18 Million More
Over 115,000 health and care workers died during the COVID-19 pandemic. As a physician who’s cared for patients with COVID-19, malaria and Ebola, I’ve seen too many colleagues make the ultimate sacrifice on the frontlines. I’m not surprised experts responding to TIME’s survey ranked bolstering the world’s public health workforce, particularly in rural and remote regions, as one of the top five of nearly 50 strategies to prepare for the next pandemic. But I’m concerned they ranked this the least feasible strategy amongst the top five. Experts ranked high the need for new systems to raise ...
Source: TIME: Health - June 10, 2021 Category: Consumer Health News Authors: Raj Panjabi Tags: Uncategorized COVID-19 health Magazine Source Type: news

Researchers make first-ever discovery of Zika virus RNA in free-ranging African bats
(Colorado State University) Dr. Anna Fagre, a researcher at CSU's Center for Vector-Borne Infectious Diseases, said detection of nucleic acid in bats in the wild indicates that they are naturally infected or exposed through the bite of infected mosquitoes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2021 Category: International Medicine & Public Health Source Type: news

Africa: We're a Step Closer to Figuring Out Why Mosquitoes Bite Some People and Not Others
[The Conversation Africa] Mosquitoes contribute to the transmission of life-threatening diseases that include Zika, dengue, chikungunya, Rift Valley fever and malaria. Of these, malaria carries the most risk accounting for 229 million cases and more than 400,000 deaths in 2019. Africa accounted for 67% (274 000) of all malaria deaths worldwide. (Source: AllAfrica News: Malaria)
Source: AllAfrica News: Malaria - May 19, 2021 Category: Infectious Diseases Source Type: news

Laboratory-Associated Zika Virus Disease, U.S., 2016-2019 Laboratory-Associated Zika Virus Disease, U.S., 2016-2019
A new report highlights the potential risk for Zika infection among laboratory workers due to occupational exposure to the virus.Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2021 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Scarred by Zika, some Brazilian women avoid pregnancy during pandemic
The fear of bearing children in another infectious-disease outbreak is starting to show in the country’s declining birthrates, a professor says. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - May 17, 2021 Category: Consumer Health News Authors: Letícia Marteleto Source Type: news

Scientists rewrite the genesis of mosquito-borne viruses
(Monash University) Better designed vaccines for insect-spread viruses like dengue and Zika are likely after researchers discovered models of immature flavivirus particles were originally misinterpreted.Researchers from The University of Queensland and Monash University have now determined the first complete 3D molecular structure of the immature flavivirus, revealing an unexpected organization. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2021 Category: Infectious Diseases Source Type: news

T Cell-Boosting Zika Vaccine Protects Mice from the Virus
By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar... (Source: The Scientist)
Source: The Scientist - May 12, 2021 Category: Science Tags: News & Opinion Source Type: news

One Health Approach Key to Tackling Africa ’s Challenges
COVID-19 has shown that we need to act fast as changes at the interface of humans, livestock and wildlife are driving increased risk of emerging disease threats across the globe. Credit: Marc-André Boisvert/IPSBy Olanike AdeyemoIBADAN, Nigeria, May 11 2021 (IPS) The COVID-19 pandemic has shown us that global health challenges cannot be solved only by health sector interventions. Many of the recent epidemics — Ebola, Zika and even Covid-19 — are emerging infectious diseases transmissible from wildlife species. In addition, other global health challenges greatly impact people, livestock, wildlife and agri...
Source: IPS Inter Press Service - Health - May 11, 2021 Category: International Medicine & Public Health Authors: Olanike Adeyemo Tags: Africa Headlines Health TerraViva United Nations Source Type: news

Genetically Modified Mosquitoes Have Come to the U.S. Will They Work?
“Our Mosquito Project Takes Flight,” reads a baby-blue billboard off US-1 in the Florida Keys, alongside an image of an insect tracing a path in the shape of a heart. Sponsored by the local mosquito control board and U.K.-based biotech firm Oxitec, the ad promotes a contentious plan to release millions of genetically modified Aedes aegypti mosquitoes here to test a new method of bioengineered pest control. It’s the first-ever such experiment in the United States, and one that has turned this chain of sun-soaked island communities into a battleground over scientific truth, government authority, and humanit...
Source: TIME: Health - May 9, 2021 Category: Consumer Health News Authors: Alejandro de la Garza / Florida Keys, Fl. Tags: Uncategorized Source Type: news

What Are Some Etiologies for Intellectual Disability?
Discussion “Intellectual disability (ID) is a neurodevelopmental disorder that is characterized by deficits in both intellectual functioning and adaptive function whose onset is in the development period.” Global developmental delay (GDD) is used to describe children from 0-5 years old with significant delays in 2 or more developmental areas. These delays may be transient but up to 2/3 of children with GDD will have ID. Overall 1-3% of the general population has ID which makes it very common. Most children with GDD/ID are identified because of delays in meeting milestones or general academic achievement. ID pat...
Source: PediatricEducation.org - May 3, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participa...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

$1.9 million award could keep Zika virus at bay
(University of California - Riverside) A UC Riverside virologist has won a $1.9 million award to investigate how Zika virus uses a protein, NS5, to beat the human immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2021 Category: International Medicine & Public Health Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

LSU Health New Orleans study discovers source of Zika neurodevelopmental defects
(Louisiana State University Health Sciences Center) A study led by Edward Wojcik, PhD, Associate Professor of Biochemistry& Molecular Biology at LSU Health New Orleans School of Medicine, identified how microcephaly (abnormally small heads) and blindness may develop in Zika-infected fetuses, as well as a new way to potentially prevent these neurodevelopmental defects. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 6, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for eve...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

UConn researcher develops successful Zika vaccine in preclinical studies
(University of Connecticut) Paulo Verardi from UConn's College of Agriculture, Health and Natural Resources has demonstrated the success of a vaccine against Zika virus and recently published his findings in Scientific Reports. The vaccine was generated using Verardi's novel patent-pending platform technology. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 1, 2021 Category: Biology Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine
New Brunswick, NJ (March 17, 2021) – We welcome the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson & Johnson’s single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in persons aged 18 years and above. SAGE advises WHO on global vaccine and immunization policies and its recommendations for use provide guidance on the use of vaccines supplied through the COVAX Facility, a global risk-sharing mechanism for pooled procurement and ...
Source: Johnson and Johnson - March 17, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study of mosquito protein could lead to treatments against life-threatening viruses
Protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - March 10, 2021 Category: American Health Source Type: news

Study of mosquito protein could lead to treatments against life-threatening viruses
(NIH/National Institute of Environmental Health Sciences) The mosquito protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika and weakly inhibits coronaviruses, according to scientists at the National Institutes of Health (NIH) and their collaborators. The researchers found that AEG12 works by destabilizing the viral envelope, breaking its protective covering. The findings could lead to therapeutics against viruses that affect millions of people around the world. The research was published online in PNAS. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 10, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipa...
Source: Johnson and Johnson - March 5, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

NIDCR Science News - March 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. A Search for Cell Identity NIDCR's Dr. Roxane Tussiwand studies how immune cells are shaped by their surroundings NIDCR • February 22, 2021 The Scarred Villain: Study Explores Neurocognitive Basis of Bias Against People Who Look DifferentUniversity of Pennsylvania • February 12, 2021 Study Reveals C...
Source: NIDCR Science News - March 2, 2021 Category: Dentistry Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agai...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are e...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Scientists reveal details of antibodies that work against Zika virus
(Biophysical Society) The Zika outbreak of 2015 and 2016 is having lasting impacts on children whose mothers became infected with the virus while they were pregnant. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 25, 2021 Category: Infectious Diseases Source Type: news

Models to predict dengue, zika and yellow fever outbreaks are developed by researchers
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Scientists will monitor areas in which these diseases are endemic, such as S ã o Paulo, the Amazon, the Pantanal and Panama, to investigate the factors that trigger outbreaks (monkey being examined in Manaus á rea. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2021 Category: International Medicine & Public Health Source Type: news

Scientists use machine-learning approach to track disease-carrying mosquitoes
(Utah State University) A team of researchers from Utah State University, University of California, Davis and Yale University are using a machine-learning approach to map landscape connectivity of the species Aedes aegypti, the so-called Yellow Fever mosquito, which is a primary vector for transmission of viruses causing dengue fever, chikungunya and Zika. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2021 Category: Biology Source Type: news

Zika Vaccine Candidate Shows Promise in Phase 1 Trial Zika Vaccine Candidate Shows Promise in Phase 1 Trial
A Zika virus vaccine candidate prompted antibody responses in 80% of individuals who received two doses in a phase 1 study.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - February 19, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our u...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 16, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen-Cilag International N.V., has submitted a conditional Marketing Authorisation Application (cMAA) to the European Medicines Agency (EMA) seeking authorisation for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial.“Throughout Europe, there remains an urgent need for additional COVID-19 vaccines, and today’s submission is a significant step forward in ensuring the European Un...
Source: Johnson and Johnson - February 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Drought restrictions had side benefit: Lowering risk of mosquito-borne disease
Shallow pools of water on lawns are ideal breeding grounds for the mosquitoes that transmit West Nile virus, the most common mosquito-borne disease in the United States.A new study by scientists from UCLA and three other universities found that reducing shallow pools of water where the insects lay their eggs is key to preventing the spread of the virus.The study, funded by a grant from the UC Office of the President and published in the journal Environmental Science and Technology, found that California ’s water-use restrictions during the statewide drought from 2012 to 2016 led to a decrease in the number of mosquit...
Source: UCLA Newsroom: Health Sciences - February 16, 2021 Category: Universities & Medical Training Source Type: news

Zika vaccine shows promise in early trials
A vaccine against Zika produced immunity to the mosquito-borne virus for up to a year in at least 80% of those who received it, a study published Monday by the Annals of Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 15, 2021 Category: Consumer Health News Source Type: news

Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news

International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women's Day is March 8th!  Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Ann Anderson Walk'at the Cochrane Colloquium to raise money for...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news